A cross-institutional team of clinical IT staff and computational biologists from several departments at Weill Cornell Medicine has successfully linked IPM reports into the Epic electronic medical record (EMR) management system in use by Weill Cornell Physicians in a highly detailed, computer-readable format. Read more
Richard Furman, M.D., argues that a partial, ongoing response on novel agent therapy may be preferable for chronic lymphocytic leukemia patients. Read more
A $4 million grant gives Columbia, Weill Cornell Medicine, NewYork-Presbyterian, and NYC Health + Hospitals/Harlem a key role in new NIH precision medicine cohort program Read more
Meyer Cancer Center researchers are part of an international team encouraging advanced prostate cancer patients to get genetic testing for DNA-repair gene mutations. Read more
Weill Cornell Medicine, NewYork-Presbyterian and Columbia University Medical Center are among nearly 200 physician group practices and 17 health insurance companies participating in the Medicare arm of the Oncology Care Model, which includes more than 3,200 oncologists. Read more
The FDA has granted an orphan drug designation to the STAT3-targeted agent napabucasin as a treatment for patients with gastric or gastroesophageal junction cancer, based on early-phase research by Manish Shah, M.D. Read more
The New York City Chapter of The Leukemia & Lymphoma Society (LLS) has announced John P. Leonard, M.D., as its 2016 Manhattan Light The Night® corporate chair. Read more
For older patients with small (T1a) renal cancer, percutaneous ablation is associated with much lower costs than partial or radical nephrectomy, according to Adam D. Talenfeld, M.D. Read more
Certain types of cancer may be even more shifty and difficult to target than previously thought, due to continuous changes in cell programming. Read more